COMMUNIQUÉS West-GlobeNewswire

Precision Optics to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
09/06/2026
LITTLETON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/06/2026
PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
09/06/2026
Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specifically Major transplantation conference in Boston will create [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/06/2026
RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired [...]
Vireo Growth Inc. Appoints BDO as its New Auditor
09/06/2026
MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOD) (“Vireo” or the “Company”) today announced the appointment of BDO USA, P.C. (“BDO”) as the Company’s new independent registered [...]
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
09/06/2026
MOUNTAIN VIEW, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Lakefront Announces Initiation of €50 Million Stock Repurchase Program
09/06/2026
Mechelen, Belgium ; June 9, 2026, 22:01 CET; regulated information – Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), under which the [...]
Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026
09/06/2026
Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo: FR0013233012 / IVA Web site: www.inventivapharma.com Date Number of Shares Outstanding Total Voting Rights, Gross (1) Total [...]
Applied Biologics Receives FDA Clearance to Advance BIOxHEAL Into Phase 3 Clinical Development for Diabetic Foot Ulcers
09/06/2026
SCOTTSDALE, Ariz., June 09, 2026 (GLOBE NEWSWIRE) -- Applied Biologics , a biopharmaceutical company developing novel biologic therapies for chronic wounds, tissue repair, and degenerative disease, today announced that [...]
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
09/06/2026
PRESS RELEASE AB SCIENCE IS INVITED TO PRESENT AT THE 2026 ENCALS ANNUAL MEETING THE SURVIVAL DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS Masitinib treatment has been linked to a 5-year [...]
AB Science présentera, lors du congrès annuel 2026 de l'ENCALS, les données de survie issues du programme clinique du masitinib dans la SLA
09/06/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE PRÉSENTERA, LORS DU CONGRÈS ANNUEL 2026 DE L'ENCALS, LES DONNÉES DE SURVIE ISSUE DU PROGRAMME CLINIQUE DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE Le traitement avec le masitinib [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2026
09/06/2026
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2026 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 mai 2026
09/06/2026
Nombre total de droits de vote et d’actions composant le capital social au 31 mai 2026 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
FDA Expands Sunscreen Options for the First Time in 20 Years
09/06/2026
Silver Spring, Md., June 09, 2026 (GLOBE NEWSWIRE) -- Today, the U.S. Food and Drug Administration added bemotrizinol to the list of permitted sunscreen active ingredients, marking a significant milestone in the agency' [...]
Ally Medical ER Is Coming to Magnolia
09/06/2026
A new 24/7 emergency room is coming to Montgomery County's fastest-growing community, designed with local families in mind MAGNOLIA, Texas, June 09, 2026 (GLOBE NEWSWIRE) -- Ally Medical Emergency Room has announced [...]
Koi Peptides Survey Finds 75% of Lab Researchers Cite Sourcing Quality as Top Concern
09/06/2026
Cheyenne, WY, June 09, 2026 (GLOBE NEWSWIRE) -- A new Koi Peptides survey of 412 laboratory researchers found that 75% rank sourcing quality among their top concerns when buying research peptides, placing it above price [...]
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
09/06/2026
OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”), today announced that it has entered into definitive agreements for a registered direct offering and [...]
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
09/06/2026
MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, [...]
Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
09/06/2026
BEDMINSTER, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- Alembic Therapeutics, LLC announces the acquisition of NUVESSA ® (metronidazole vaginal gel 1.3%), an FDA-approved prescription medication indicated for the treatment [...]

Pages